A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

What this study is testing ClinicalTrials.gov NCT03492580 ↗

Description as written by the study sponsor.

The primary purpose of study is to estimate the incidence and comparative effect on health outcomes: 1) hospitalization for heart failure, 2) below knee lower extremity amputation. The date of first exposure to the particular drug(s) in the database, where the exposure start is between 1-April-2013 to 15-May-2017 and outcome data for these participants will be analyzed and reported in this study.

Treatments tested

• Canagliflozin Drug

  No intervention or treatment assignment imposed by this study. Participants received canagliflozin as a part of routine clinical practice.

• Empagliflozin Drug

  No intervention or treatment assignment imposed by this study. Participants received empagliflozin as a part of routine clinical practice.

• Dapagliflozin Drug

  No intervention or treatment assignment imposed by this study. Participants received dapagliflozin as a part of routine clinical practice.

• Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Drug

  No intervention or treatment assignment imposed by this study. Participants received DPP-4 inhibitor as a part of routine clinical practice. DPP-4 inhibitors includes: alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin.

• Glucagon-like Peptide-1 (GLP-1) Agonist Drug

  No intervention or treatment assignment imposed by this study. Participants received GLP-1 agonist as a part of routine clinical practice. GLP-1 agonists includes: albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide.

• Anti-hyperglycemic Agents (AHA) Drug

  No intervention or treatment assignment imposed by this study. Participants received other selected AHA as a part of routine clinical practice. Other select AHAs includes: acarbose, bromocriptine, miglitol, nateglinide, repaglinide.

• Thiazolidinediones (TZD) Drug

  No intervention or treatment assignment imposed by this study. Participants received TZD as a part of routine clinical practice. TZDs includes: pioglitazone, rosiglitazone, troglitazone.

• Sulfonylureas (SU) Drug

  No intervention or treatment assignment imposed by this study. Participants received SU as a part of routine clinical practice. SUs includes: glipizide, glyburide, glimepiride, chlorpropamide, tolazamide, tolbutamide, acetohexamide

• Insulin Drug

  No intervention or treatment assignment imposed by this study. Participants received Insulin as a part of routine clinical practice.